A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

Trial Profile

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Istiratumab (Primary) ; MM-151 (Primary) ; Seribantumab (Primary) ; Trametinib (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 19 May 2016 Treatment table, drug descriptors and purpose were modified to reflect the changes presented in a Merrimack Pharmaceuticals media release.
    • 04 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top